Bill Giving Medicare Drug-Price Negotiating Power Set to Become Law

President Joe Biden seated in the Oval Office
President Biden is scheduled to sign historic drug pricing legislation with implications for the 340B program later today.

President Joe Biden this afternoon is scheduled to sign legislation that for the first time will let Medicare negotiate the prices of certain costly prescription drugs and require drug makers to pay Medicare rebates when their prices outpace inflation. 

House

Read More »

Senate Panel Wants HRSA to Tell How It Has Responded to Drug Makers’ 340B Pricing Denials

U.S. Senate Appropriations Committee room
The U.S. Senate Appropriations Committee wants a report from HRSA "on actions taken to safeguard covered entities’ lawful access to discounted drugs.”

The U.S. Senate Appropriations Committee wants federal healthcare officials to tell it what they have done about drug manufacturers’ denials of 340B pricing when covered entities use contract pharmacies.

The committee included the directive to the U.S. Health Resources and

Read More »

Senate Rejects 340B-Related Amendment to Major Drug Pricing and Climate Change Bill

Sen. John Kennedy (R-LA) speaking on Senate floor
U.S. Sen. John Kennedy's (R-La.) failed amendment to the Inflation Reduction Act would have required health centers to make insulin and EpiPens available at or below 340B price and would have helped cover centers' direct costs of doing so. A leading health center advocate panned the amendment.

The U.S. Senate on Sunday rejected a Republican amendment to Democratic drug pricing and climate change legislation that would have required federally qualified health centers to make insulin and injectable epinephrine available to patients at or below 340B price.

But

Read More »

Senate Passes Historic Bill that Would Let Medicare Negotiate Some Drugs’ Prices

Sen. Chuck Schumer (D-NY) speaking on Senate floor
Senate Majority Leader Chuck Schumer (D-N.Y.) opens debate Sunday on historic legislation that would let Medicare negotiate prices on a small number of high-cost single-source drugs. The House is expected to pass the bill this Friday.

The U.S. Senate on Sunday passed historic legislation to let Medicare negotiate the prices of a small number of costly medicines and require drug manufacturers to pay Medicare rebates when prices paid by Medicare rise faster than inflation.

Language in

Read More »

Vermont Passes Bill Enhancing 340B Anti-Discriminatory Protections but Measure Aimed at Drug Manufacturers Fails

Vermont State House building
Vermont recently extended its prohibition on discrimination by PBMs against 340B entities but did not require drug manufacturers to provide 340B-priced drugs to contract pharmacies.

The state of Vermont has passed a bill extending its prohibition on discrimination by pharmacy benefit managers (PBMs) against 340B covered entities, which was originally passed in June 2021 as part of the state’s 2022 budget. 

The bill was quietly

Read More »

Providers March on U.S. Capitol Grounds to “Defend 340B”

340B program advocates with signs in front of the US Capitol building
Safety-net provider advocates marched on the U.S. Capitol grounds yesterday to raise awareness about threats to the 340B drug pricing program.

About 100 safety-net provider advocates marched and chanted yesterday on the grounds of the U.S. Capitol to raise awareness in Congress and beyond about threats to the 340B drug pricing program.

The demonstration, organized by Community Voices for 340B (CV340B),

Read More »

Senate Democrats Say They Are on Track to Pass Drug Pricing Bill Before Aug. 8

U.S. Senate chamber viewed from public gallery
Senate Democrats are still pushing to pass drug pricing legislation before the chamber begins its summer break on Aug. 8.

Senate Democrats said yesterday they would know this week whether an updated Senate drug pricing bill meets the criteria for passage via budget reconciliation, which requires just 50 Democratic votes. The bill remains on track for a floor vote before

Read More »

340B Report Publisher and CEO: What to Expect Following Midterm Elections

A roll of I Voted, Yo Vote stickers
Look for the GOP to try again to put more restrictions on the 340B program if the party takes over the U.S. House, 340B Report Publisher and CEO Ted Slafsky says.

Congress’ attitude toward the 340B program will likely change in 2023 and 2024 because of November’s midterm election results, 340B Report Publisher and CEO Ted Slafsky predicts in his latest column for Omnicell.

It is customary for the party that

Read More »

Senate Democrats Optimistic About Passing Drug Pricing Bill Before August Recess

Rachel Cohrs and Sen. Ron Wyden headshots
Senate Finance Chair Ron Wyden (right) said yesterday during a webinar moderated by STAT correspondent Rachel Cohrs (left) that Senate Democrats want to pass drug pricing legislation "right now, before everybody leaves for August."

U.S. Senate Democrats are hopeful that drug pricing legislation will be passed by early next month via a budget reconciliation process requiring just 50 Democratic votes, a Democratic source with knowledge of the process told 340B Report.

“Our expectation is, we’re

Read More »

News Alert

181 House Members Prod HHS to Start Fining Drug Makers for “Unlawful” 340B Overcharges Involving Contract Pharmacies

East elevation of the U.S. Capitol building
181 bipartisan U.S. House members on Friday urged HHS to quickly fine all drug manufacturers that deny 340B pricing when covered entities use contract pharmacies.

One hundred eighty-one U.S. House members—144 Democrats and 37 Republicans—urged the Biden administration on Friday to quickly impose civil monetary penalties against all drug manufacturers that restrict access to 340B pricing when covered entities use contract pharmacies.

“Manufacturers have received

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live